Drug
Etrumadenant
Etrumadenant: highest development phase Phase 2, developed by Arcus Biosciences. 5 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Arcus Biosciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| Etrumadenant (AB928) NCT05024097 | Phase 2 | Rectal Cancer |
| Etrumadenant NCT03719326 | Phase 1 | TNBC - Triple-Negative Breast Cancer |
| Etrumadenant NCT05154136 | Phase 1 | Healthy Participants |
| Etrumadenant NCT03629756 | Phase 1 | Non-small Cell Lung Cancer |
| etrumadenant NCT03720678 | Phase 1 | GastroEsophageal Cancer |
Latest
No recent events.
Follow Etrumadenant on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.